chantal, Author at Scancell - Page 7 of 11

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody^® iSCIB1+

by chantal | Jul 22, 2025 | Latest News, News

Share Option Exercise

by chantal | Jul 16, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Cancer vaccine data due soon; Glymab developments too

by chantal | Jul 10, 2025 | GlyMab, iSCIB1+, Modi-1, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Clinical & Corporate Update: Active Immunotherapy for a Cancer-Free Future

by chantal | Jun 25, 2025 | Investor Presentations

Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+

by chantal | Jun 25, 2025 | Immunobody, iSCIB1+, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

« Older Entries

Next Entries »